-
-
-
-
-
-
-
BridgeBio's encaleret shows symptom gains in ADH1 phase 3 trial
-
-
-
-
-
-
-
FDA accepts BridgeBio's NDA for oral infigratinib for achondroplasia
-
-
-
-
-
-
-
AstraZeneca closes $2 billion equity stake in Summit Therapeutics
-
-
-
-
-
-
-
Dyne Therapeutics (DYN) PT Lowered to $32 at H.C. Wainwright
-
-
-
-
-
-
-
AstraZeneca invests $2B in Summit Therapeutics preferred shares
-
-
-
-
-
-
-
FDA grants Jaguar Health fee waivers for two drugs in fiscal 2027
-
-
-
-
-
-
-
Spruce Biosciences (SPRB) Reiterated at Market Outperform by Citizens
-
15,908 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


